Table 2. Adverse events and end-of-cycle 1 dose-limiting toxicities.

	Dosage by grade
	2.5 mg Daily (n=6)		5 mg Daily (n=11)		10 mg Daily (n=3)		All (n=20)
Adverse eventsb	1/2	3/4	1/2	3/4	1/2	3/4	Any grade
Haematologic toxicities
Anaemia	5	0	10	1	3	0	19
Neutropenia	3	1	3	6	1	2	16
Thrombocytopenia	2	0	3	1	2	2	12
Febrile neutropenia	0	0	0	1	0	0	1
Leukopenia	4	1	4	4	2	0	15
Nonhaematologic toxicities
Anorexia	2	0	3	0	1	0	6
Vomiting	0	0	2	0	0	0	1
Stomatitis	2	0	5	0	1	0	8
Diarrhoea	0	0	2	0	1	0	3
Neuropathy	1	0	3	1	2	0	7
Pain	2	0	6	0	2	0	10
AST increased	1	0	4	0	1	0	6
ALT increased	1	0	5	0	0	0	6
Hyperglycemia	6	0	9	0	2	1	18
Hypertriglycemia	3	0	2	0	2	0	7
Itching	0	0	2	0	2	0	4
Pneumonitis	0	0	1	0	0	0	1
Dose-limiting toxicity, cycle 1
Thrombocytopenia	0	0	0	1a	0	1	2
Fever with grade 4 neutropenia	0	0	0	1a	0	0	1
Hyperglycemia	0	0	0	0	0	1	1

Abbreviations: ALT=alanine aminotranferease; AST=aspartate aminotransferase.

^aTwo dose-limiting toxicities in the same person.

^bA patient with multiple occurrence of an adverse event was counted only once in the adverse event category. A patient with multiple severity ratings for an adverse event was only included under the maximum rating.